This study aimed to evaluate the clinical efficacy of the antiglycopeptidolipid core IgA antibody test for screening NTM-PD in a large bronchiectasis cohort and to assess whether the test can discriminate patients with NTM-PD from those with NTM isolation who do not meet the diagnostic criteria for NTM-PD. This evidence concerns the gene CD79A and bronchiectasis.